Last 39 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 45.82 | — | 24.04 | 16.36 | 28.64 | 333.67 | 29.10 | 55.72 | — | — | 84.44 | — | — | 17.58 | 9.69 | — | — | — | — | — | — |
| — | — | -17.4% | -70.6% | — | — | -65.5% | — | — | — | +771.7% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.01 | 1.96 | 1.78 | 1.41 | 1.26 | 1.04 | 0.90 | 0.98 | 0.84 | 0.92 | 0.72 | 0.71 | 0.60 | 0.27 | 0.20 | 0.09 | 0.12 | 0.14 | 0.21 | 0.31 | 0.33 |
| — | +89.2% | +98.2% | +45.0% | +49.6% | +13.0% | +24.7% | +38.2% | +40.1% | +237.4% | +260.1% | +644.9% | +385.0% | +93.9% | -6.6% | -69.8% | -62.9% | -62.8% | -41.0% | -39.1% | +0.7% | |
| P/B Ratio | 1097.01 | 10.55 | 48.55 | — | 686.31 | — | — | — | — | — | — | — | 24.13 | 3.52 | 2.63 | 1.30 | 1.44 | 1.41 | 2.52 | 1.47 | 1.86 |
| — | — | — | — | — | — | — | — | — | — | — | — | +1572.5% | +149.5% | +4.4% | -11.6% | -22.6% | -29.5% | +30.7% | -46.9% | -1.5% | |
| P/FCF | 159.17 | 27.85 | — | — | 11.74 | 7.86 | 11.37 | — | 6.46 | 5.32 | 17.49 | — | 3.55 | 2.48 | — | 0.41 | — | 1.01 | — | 2.38 | 3.96 |
| — | +254.3% | — | — | +81.8% | +47.7% | -35.0% | — | +81.8% | +114.5% | — | — | — | +146.7% | — | -82.7% | — | -63.8% | — | +27.8% | +76.5% | |
| EV / EBITDA | 12.79 | 16.63 | 10.76 | 8.85 | 9.95 | 26.57 | 7.45 | 8.15 | 8.70 | 8.71 | 7.79 | 25.45 | 14.55 | 6.38 | 5.89 | 7.88 | 8.04 | 7.26 | — | 10.11 | 11.59 |
| — | -37.4% | +44.5% | +8.5% | +14.5% | +205.2% | -4.4% | -68.0% | -40.2% | +36.4% | +32.4% | +222.9% | +81.0% | -12.1% | — | -22.0% | -30.7% | -24.4% | — | +17.7% | +11.4% | |
| EV / EBIT | 20.93 | 33.42 | 14.29 | 11.53 | 14.62 | 24.90 | 10.93 | 13.86 | 26.63 | 15.90 | 13.66 | — | — | 11.48 | 10.03 | 18.30 | 19.81 | 17.25 | — | 35.03 | 47.56 |
| — | +34.2% | +30.7% | -16.8% | -45.1% | +56.6% | -20.0% | — | — | +38.5% | +36.2% | — | — | -33.5% | — | -47.8% | -58.3% | -34.5% | — | +96.1% | +65.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 37.6% | 38.7% | 42.0% | 44.3% | 36.5% | 34.9% | 39.5% | 36.8% | 36.0% | 38.4% | 35.6% | 36.1% | 36.5% | 37.5% | 36.7% | 32.0% | 35.3% | 35.6% | 35.8% | 35.1% | 31.0% |
| — | +10.9% | +6.3% | +20.4% | +1.4% | -9.0% | +10.9% | +1.9% | -1.5% | +2.3% | -3.0% | +13.0% | +3.5% | +5.3% | +2.5% | -8.9% | +14.0% | -5.2% | -9.7% | -9.7% | -5.4% | |
| Operating Margin | 14.0% | 11.1% | 18.3% | 19.8% | 14.1% | -0.0% | 15.4% | 14.4% | 10.4% | 12.6% | 13.6% | -1.6% | 2.3% | 12.2% | 13.4% | 6.2% | 5.9% | 8.1% | -35.5% | 4.7% | 2.1% |
| — | +74329.5% | +19.3% | +37.0% | +35.5% | -100.1% | +13.0% | +985.1% | +351.0% | +3.6% | +1.8% | -126.4% | -61.1% | +50.1% | +137.6% | +31.9% | +183.9% | +50.7% | -383.1% | -49.7% | -47.4% | |
| Net Margin | 2.4% | -0.9% | 7.2% | 8.6% | 4.3% | 0.3% | 3.1% | 1.8% | -4.3% | -0.0% | 0.9% | -13.9% | -16.0% | 1.6% | 2.0% | -1.2% | -0.7% | -0.5% | -21.6% | -0.4% | -1.2% |
| — | -386.2% | +134.1% | +391.4% | +201.2% | +1460.4% | +262.3% | +112.6% | +73.4% | -101.4% | -57.1% | -1016.4% | -2150.1% | +416.8% | +109.2% | -187.4% | +40.2% | +38.5% | -895.2% | -131.9% | -99.5% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1208.4% | -2.0% | 162.4% | — | 588.2% | — | — | — | — | — | — | -410.1% | -78.1% | 5.2% | 6.9% | -3.7% | -2.0% | -1.3% | -39.3% | -0.5% | -1.6% |
| — | — | — | — | — | — | — | — | — | — | — | -10859.6% | -3734.6% | +492.1% | +117.6% | -600.8% | -24.9% | -25.0% | -1142.8% | -128.8% | -89.2% | |
| ROA | 2.0% | -0.2% | 1.6% | 1.7% | 1.0% | 0.1% | 0.7% | 0.4% | -0.9% | -0.0% | 0.2% | -2.6% | -2.8% | 0.3% | 0.3% | -0.2% | -0.1% | -0.1% | -3.0% | -0.1% | -0.2% |
| — | -344.3% | +138.6% | +385.6% | +208.0% | +1600.0% | +283.8% | +113.4% | +67.6% | -101.7% | -47.1% | -1314.5% | -2340.8% | +486.0% | +110.7% | -239.4% | +30.0% | +35.9% | -936.8% | -132.7% | -113.5% | |
| ROIC | 13.0% | 2.2% | 4.2% | 4.4% | 3.6% | -0.0% | 3.4% | 3.1% | 2.3% | 2.6% | 2.7% | -0.3% | 0.4% | 1.9% | 2.1% | 0.9% | 0.9% | 1.1% | -4.9% | 0.6% | 0.3% |
| — | +60822.2% | +23.1% | +42.8% | +56.4% | -100.1% | +27.2% | +1129.7% | +504.2% | +31.5% | +29.1% | -134.1% | -57.9% | +74.7% | +142.2% | +52.9% | +223.4% | +58.2% | -387.8% | -51.3% | -44.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 458.91 | 5.12 | 23.87 | — | 458.91 | — | — | — | — | — | — | — | 44.87 | 14.66 | 15.63 | 17.59 | 13.62 | 13.19 | 15.19 | 6.76 | 7.52 |
| — | — | — | — | — | — | — | — | — | — | — | — | +229.5% | +11.1% | +2.9% | +160.1% | +81.0% | +80.4% | +108.2% | -15.1% | -10.5% | |
| Debt / EBITDA | 4.23 | 22.08 | 14.41 | 14.49 | 16.71 | 49.78 | 15.06 | 16.07 | 18.27 | 17.90 | 18.04 | 61.32 | 38.67 | 21.11 | 20.84 | 30.81 | 29.30 | 26.97 | — | 35.33 | 39.91 |
| — | -55.6% | -4.3% | -9.8% | -8.5% | +178.1% | -16.6% | -73.8% | -52.8% | -15.2% | -13.4% | +99.0% | +32.0% | -21.7% | — | -12.8% | -26.6% | -17.9% | — | +22.8% | +6.5% | |
| Current Ratio | 2.17 | 1.87 | 2.20 | 2.47 | 2.17 | 2.13 | 1.43 | 1.40 | 1.41 | 1.38 | 1.33 | 1.65 | 1.63 | 1.91 | 1.83 | 1.86 | 1.88 | 1.74 | 1.56 | 2.31 | 2.24 |
| — | -12.3% | +54.0% | +75.9% | +54.2% | +54.3% | +7.4% | -15.1% | -13.6% | -27.8% | -27.1% | -11.0% | -13.2% | +10.3% | +16.9% | -19.5% | -16.4% | -26.2% | -32.7% | -5.8% | -2.1% | |
| Quick Ratio | 1.48 | 1.24 | 1.44 | 1.59 | 1.48 | 1.42 | 0.88 | 0.84 | 0.86 | 0.84 | 0.82 | 0.97 | 0.94 | 1.16 | 1.12 | 1.11 | 1.17 | 1.07 | 1.03 | 1.46 | 1.52 |
| — | -12.8% | +63.0% | +88.0% | +71.4% | +69.6% | +7.9% | -12.9% | -8.2% | -27.6% | -27.1% | -12.3% | -19.6% | +8.0% | +9.1% | -24.1% | -23.1% | -31.9% | -33.5% | -12.7% | -2.9% | |
| Interest Coverage | 1.58 | 1.26 | 2.65 | 2.68 | 1.98 | 0.92 | 1.79 | 1.66 | 0.75 | 1.24 | 1.31 | -0.15 | -0.40 | 1.45 | 1.58 | 0.81 | 0.84 | 1.05 | -5.53 | 0.70 | 0.52 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 39 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AMRX stock.
Amneal Pharmaceuticals, Inc.'s current P/E is 45.8x. The average P/E over the last 3 quarters is 23.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Amneal Pharmaceuticals, Inc.'s current operating margin is 14.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Amneal Pharmaceuticals, Inc.'s business trajectory between earnings reports.